NAME
J. Wesson Ashford, M.D, Ph.D.
POSITION TITLE
Clinical Professor (affiliated), Stanford University
EDUCATION/TRAINING
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
University of California, Berkeley, CA
BA
1970
Biological Sciences
UCLA, School of Medicine, Los Angeles, CA
MD
1974
Medicine
UCLA, Neuropsychiatric Institute, Los Angeles, CA
1979
Psychiatry
UCLA, Brain Research Institute, Los Angeles, CA
1981
Mental Health
UCLA, Graduate School
PhD
1984
Neuroscience
PROFESSIONAL APPOINTMENTS
10/79 - 06/80 Associate Director, Geriatric Neuropsychiatry Inpatient Unit, UCLA / NPI
07/80 - 06/85 Director, Geriatric Psychiatry Outpatient Clinic, UCLA / NPI (50% time, while in PhD program)
08/84 - 06/85 Research Director, Geriatric Psychiatry Ward, Brentwood VA Hospital (50% time)
09/85 - 12/90 Consultant, Geriatric Psychiatry, Adolf Meyer State Mental Hospital, Illinois
01/91 - 12/92 Staff Psychiatrist, VAMC, Martinez, California
12/92 - 3/03 Staff Psychiatrist, VAMC, Lexington, Kentucky
10/94 - 3/03 Director, Memory Disorders Clinic, VAMC, Lexington
07/00 - 9/01 Acting Chief, Mental Health Service, VAMC, Lexington
03/03 - pres. Staff Psychiatrist, VA, Palo Alto, California
07/07 – pres Director, War-Related Illness and Injury Study Center (VA Palo Alto Health Care System)
ACADEMIC APPOINTMENTS
07/83 - 06/85 Adjunct Lecturer, Department of Psychiatry, UCLA
07/85 - 12/90 Assistant Professor, Department of Psychiatry, Southern Illinois University (Springfield)
01/91 - 12/92 Associate Professor, Department of Psychiatry, University of California, Davis
12/92 - 06/03 Associate Professor, Departments of Psychiatry and Neurology and Sanders Brown Center on
Aging, University of Kentucky (06/95 Tenure Granted)
12/92 - 6/01 Vice-chair for Research, Department of Psychiatry, University of Kentucky
03/03 - pres. Senior Research Scientist, Stanford / VA Alzheimer Center, MIRECC, VAPAHCS
09/09 - pres. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences, Stanford
HONORS
05/85 - Finalist, Lindsley Prize (Best Dissertation in Behavioral Neuroscience), Society for Neuroscience
06/90 - Teacher of the Year, SIU Psychiatry Residency
11/93 - Clinical Digest Series--Outstanding Article (Coburn KL, Ashford JW, Moreno MA, 1993--see pub. list)
2003 – present – Scientific Advisory Board, Northern California Chapter, Alzheimer’s Association.
2005 – present – Chair, Memory Screening Advisory Board, Alzheimer’s Foundation of America.
2008 – present – Clinical Editor, Journal of Alzheimer’s Disease
MEMBERSHIPS - Active
American Association for Geriatric Psychiatry: (Program Committee, 2001-3; CME Committee, 2002-5)
American Psychiatric Association, Northern California Psychiatric Society
International Psychogeriatric Association: (Program Committee, Membership Committee, 2002, 2003)
Society for Neuroscience: (President, Sangamon Chapter, Springfiled, Illinois, 1991)
B. Selected peer-reviewed publications (in chronological order).
(Publications selected from 90 peer-reviewed publications, 11 book chapters, 30 international symposia)
1. 1981 Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF. Physostigmine and its effect on six patients with dementia. American Journal of Psychiatry, 138:829-830.
2. Ashford JW, Jarvik L. Alzheimer's disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? N Engl J Med. 1985 Aug 8;313(6):388-9.
3. 1987 Ashford JW, Rosenblatt MJ, Bekian C, Hayes T. The complete dementia evaluation: complications and complexities. The American Journal of Alzheimer's Care and Research. 9-15.
4. 1989 Small GW, Kuhl DE, Riege WH, Fujikawa DG, Ashford JW, Metter EJ, Mazziotta JC. Cerebral glucose metabolic patterns in Alzheimer's disease. Archives of General Psychiatry. 46:527-532.
5. 1989 Parks RW, Crockett DJ, Tuokko H, Beattie BL, Ashford JW, Coburn KL, Zec RF, Becker RE, McGeer PL, McGeer EG. Neuropsychological "systems efficiency" and positron emission tomography. Journal of Neuropsychiatry. 1:269-282.
6. 1989 Ashford JW, Kolm P, Colliver JA, Bekian C, Hsu LN. Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. Journal of Gerontology. 44:139-146
7. 1991 Coburn KL, Ashford JW, Moreno MA. Visual evoked potentials in dementia: selective delay of flash P2 in probable Alzheimer disease. Journal of Neuropsychiatry and Clinical Neuroscience 3:431-435.
8. 1992 Ashford JW, Kumar V, Barringer M, Becker M, Bice J, Ryan N, Vicari S. Assessing Alzheimer severity with a global clinical scale. International Psychogeriatrics 4:55-74.
9. 1992 Luchins DJ, Hanrahan P, Cohen D, Eisdorfer C, Paveza G, Ashford JW, Gorelick P, Hirschman R, Freels S, Levy P, Shaw H. Are there clinical differences between familial and non-familial Alzheimer's disease? American Journal of Psychiatry 149:1023-1027
C. Research Support
U01 AG10483 ADC-032 (PI: Galasko; site PI: Ashford) 1/1/2008 – 12/30/2010NIA/Alzheimer’s Disease Cooperative Studies - Role: site Principal Investigator - A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with PF-04494700 (TTP488) in Participants with Mild-to-Moderate Alzheimer’s Disease (ADC-032-RI) (A multi-site, trial to determine if an inhibitor for Receptor for Advanced Glycation Endpoints (RAGE), has an effect on the progression of AD).
U01 AG10483 ADC-030 (PI: Sano; site PI: Ashford) 1/1/2007 – 12/30/2012NIA/Alzheimer’s Disease Cooperative Studies - Role: site Principal Investigator - Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old (ADC-030-HBA) (A multi-site, trial to evaluate different forms of home-based assessment methods).
U01 AG 024904 (Weiner) 9/30/2004 - 8/31/2009
NIA - Role: investigator - Alzheimer’s Disease Neuroimaging Initiative (ADNI) - National study to develop uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with AD, MCI, and elderly controls, and to acquire a data repository describing longitudinal changes in brain structure and metabolism.
NAMMD15 (PI: Yesavage) 2/1/2003 – 12/31/2008
Forest Research Institute - Role: Investigator - The Effect of Memantine on Brain Structure and Chemistry in Alzheimer’s Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial - MRI scans before and after treatment with Memantine will be compared.
Completed Research Support as Principal Investigator (selected)01/96 - 2001 Progressive Deterioration of Cortical Blood Flow by Localized Anatomical Element (LOXEL) Across the Full Spectrum of Deterioration in Alzheimer's Disease. DuPont Pharmaceutical (gift of ECD).7/1/2002 - 6/30/2003 Inhibition of Alzheimer neuropathology with lithium. Univ. of Kentucky, College of Medicine ($15,000).
Co-Investigator (selected)
04/84 - 08/89 NIH; "Emission Computed Tomography of Local Cerebral Functions"; (P.I.: D. Kuhl); $2,000,000.
02/87 - 06/89 NIH; "Effects of Long Acting Anticholinesterases in Alzheimer's Disease"; (1 RO1 MKH 41821); (P.I.: R. E. Becker), $91,752.